K
Karen K. Fu
Researcher at University of California, San Francisco
Publications - 15
Citations - 3530
Karen K. Fu is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Radiation therapy & Carcinoma. The author has an hindex of 11, co-authored 15 publications receiving 3438 citations.
Papers
More filters
Journal ArticleDOI
A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003
Karen K. Fu,Thomas F. Pajak,Andy Trotti,Christopher U. Jones,Sharon A. Spencer,Theodore L. Phillips,Adam S. Garden,John A. Ridge,Jay S. Cooper,K. Kian Ang +9 more
TL;DR: Hyperfractionation and accelerated fractionation with concomitant boost are more efficacious than standard fractionation for locally advanced head and neck cancer.
Journal Article
Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma.
K. Kian Ang,Brian A. Berkey,Xiaoyu Tu,Hua Zhong Zhang,Ruth L. Katz,Elizabeth H. Hammond,Karen K. Fu,Luka Milas +7 more
TL;DR: This correlative study in a large series of patients revealed that EGFR expression, which varied considerably among HNSCCs, was a strong independent prognostic indicator for OS and DFS and a robust predictor for LR relapse but not for distant metastasis.
Journal ArticleDOI
Three-dimensional intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: the University of California-San Francisco experience.
Khalil Sultanem,Hui-Kuo G. Shu,Ping Xia,C. Akazawa,Jeanne M. Quivey,Lynn J. Verhey,Karen K. Fu +6 more
TL;DR: The experience with three-dimensional intensity-modulated radiotherapy (IMRT) in the treatment of nasopharyngeal carcinoma was good, local-regional progression-free, distant metastasis-free survival and overall survival were excellent, and the doses delivered were within the tolerance of these critical normal structures.
Journal ArticleDOI
Influence of fraction size, total dose, and overall time on local control of T1-T2 glottic carcinoma.
Quynh-Thu X. Le,Karen K. Fu,Steward Kroll,Janice K. Ryu,Jeanne M. Quivey,Thomas S. Meyler,Richard Krieg,Theodore L. Phillips +7 more
TL;DR: Total dose, fraction size, and overall time were significant factors for local control of T2 but not T1 glottic carcinomas.
Journal ArticleDOI
Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas.
Ding Jen Lee,Dennis Cosmatos,Victor A. Marcial,Karen K. Fu,Marvin Rotman,Jay S. Cooper,H. Ortiz,Jonathan J. Beitler,Ross A. Abrams,Walter J. Curran,C. Norman Coleman,Todd H. Wasserman +11 more
TL;DR: The results showed that adding Etanidazole to conventional RT produced no global benefit for patients who had advanced head and neck carcinomas, and there was a suggested benefit for Patients who had N0-1 disease, and that needs to be confirmed by another study.